According to most authors, it should be emphasized that the benefits of CVD reduction by statin therapy appear to far exceed the risk of new- onset T2DM development. However, the increased risk of incident T2DM in at least a subset of patients upon statin treatment suggests the opportunity to both monitor glycemic control and related parame- ters in these subjects, as indicated above